Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 27 |
| Active Pipeline (Recruiting Now) | 11 (3) |
| Completed vs Stopped Early | 6 / 5 (18.5%) |
| Median Closed Actual Enrollment | 68 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University | Guangzhou, Guangdong | 5 |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong | 5 |
| Hunan Cancer Hospital | Changsha, Hunan | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06079983 | JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Jiangsu Alphamab Biopharmaceuticals Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.